Ironwood Pharmaceuticals, Inc. (IRWD)
3.50
-0.27
(-7.16%)
USD |
NASDAQ |
Oct 16, 16:00
3.53
+0.03
(+0.86%)
After-Hours: 20:00
Ironwood Pharmaceuticals Research and Development Expense (Annual) : 93.26M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 93.26M |
| December 31, 2024 | 109.41M |
| December 31, 2023 | 99.41M |
| December 31, 2022 | 42.85M |
| December 31, 2021 | 68.88M |
| December 31, 2020 | 84.50M |
| December 31, 2019 | 109.46M |
| December 31, 2018 | 97.20M |
| December 31, 2017 | 148.23M |
| December 31, 2016 | 129.21M |
| Date | Value |
|---|---|
| December 31, 2015 | 108.75M |
| December 31, 2014 | 98.76M |
| December 31, 2013 | 102.38M |
| December 31, 2012 | 113.47M |
| December 31, 2011 | 86.09M |
| December 31, 2010 | 77.45M |
| December 31, 2009 | 84.89M |
| December 31, 2008 | 59.81M |
| December 31, 2007 | 57.25M |
| December 31, 2006 | 35.54M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| AbbVie, Inc. | 8.249B |
| Xencor, Inc. | 239.43M |
| Viking Therapeutics, Inc. | 344.96M |
| IDEAYA Biosciences, Inc. | 314.70M |
| BioMarin Pharmaceutical, Inc. | 700.97M |